This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): lixisenatide, ZP10, AVE0010, Lyxumia
Description: BioMedTracker has separate drug profiles for the regular release and prolonged release (PR) formulations of AVE0010. Please also see AVE0010 PR.
AVE0010 is an exendin-4 analogue to mimic glucagon-like peptide (GLP-1). It incorporates Zealand's proprietary SIP technology (Structure Inducing Probe), a peptide conjugation technology, giving it a longer plasma half-life and more stability than GLP-1 (deletion of 1 proline and adding six additional Lys residues to the C-terminus). AVE0010 can be given once-daily.
GLP-1 is an incretin hormone secreted in the small intestine and colon in response to food intake. It enhances insulin secretion when glucose levels are high, suppresses inappropriate glucagons secretion (glucagon has the opposite effect of insulin), slows gastric emptying (slowing entry of ingested nutrients into the bloodstream, hence limiting post-prandial glucose), and via actions on the brain is thought to promote satiety.
Revenue splits for this drug are BioMedTracker estimates.
In June 2000, Zealand and Elan formed a joint venture, called Betacure, to develop ZP10. On March 23, 2003, the companies terminated their joint venture. Zealand regained full commercial rights, but Elan was entitled to receive a royalty from Zealand on future revenues from ZP10.
On June 25, 2003, Aventis and Zealand Pharma signed a licensing agreement for the development and worldwide commercialization of ZP10 (AVE-0010). Aventis will receive the global rights to ZP10 and will be fully responsible for all further development, regulatory approval, manufacturing, marketing and sales of this compound. Zealand will receive an upfront payment of $10 million, and total milestone payments could total up to $100 million. Zealand would receive royalties on future product sales.
In June 2010, Zealand Pharma announced that the global licensing agreement with sanofi-aventis has been amended to provide for the...See full deal structure in Biomedtracker
Partners: Zealand Pharma A/S Alkermes plc
Additional information available to subscribers only: